Ponomareva A A, Rykova E Iu, Cherdyntseva N V, Skvortsova T E, Dobrodeev A Iu, Litviakov N V, Zav'ialov A A, Tuzikov S A, Vlasov V V, Laktionov P P
Vopr Onkol. 2011;57(3):302-7.
Blood-based methylated DNA gene RARbeta2 in circulating plasma (cir DNA) and one associated with blood cell surface were assayed in patients with non small cell lung cancer before and after combined treatment. The levels in both appeared to be significantly higher than in healthy subjects. Enhanced levels prior to treatment were associated with greater advancement of the disease and unfavorable prognosis (overall survival). After two courses of neoadjuvant therapy plus surgery methylation indices fell down to match those in healthy subjects. Our data may be instrumental in working out additional criteria to be used in diagnosis, prognosis and follow-up of patients with non small cell lung cancer.
在接受联合治疗前后的非小细胞肺癌患者中，检测了循环血浆中基于血液的甲基化DNA基因RARbeta2（cir DNA）以及一种与血细胞表面相关的物质。两者的水平似乎均显著高于健康受试者。治疗前水平升高与疾病进展更严重及预后不良（总生存期）相关。经过两个疗程的新辅助治疗加手术后，甲基化指数降至与健康受试者相当的水平。我们的数据可能有助于制定用于非小细胞肺癌患者诊断、预后和随访的额外标准。
